Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Free Cash Flow (2022 - 2025)

Gossamer Bio's Free Cash Flow history spans 4 years, with the latest figure at -$48.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 36.17% year-over-year to -$48.3 million; the TTM value through Dec 2025 reached -$171.3 million, down 4840.74%, while the annual FY2025 figure was -$171.3 million, 4840.74% down from the prior year.
  • Free Cash Flow reached -$48.3 million in Q4 2025 per GOSS's latest filing, down from -$36.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $116.3 million in Q2 2024 to a low of -$53.6 million in Q1 2022.
  • Average Free Cash Flow over 4 years is -$32.6 million, with a median of -$39.0 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: skyrocketed 404.17% in 2024, then tumbled 140.49% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$48.1 million in 2022, then skyrocketed by 30.5% to -$33.4 million in 2023, then dropped by 6.15% to -$35.5 million in 2024, then tumbled by 36.17% to -$48.3 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Free Cash Flow are -$48.3 million (Q4 2025), -$36.2 million (Q3 2025), and -$47.1 million (Q2 2025).